299897-90-8

Basic information

• Product Name: 2-NITRO-5-(1-PYRROLIDINYL)BENZENECARBOXAMIDE
• Synonyms: 2-NITRO-5-(1-PYRROLIDINYL)BENZENECARBOXAMIDE
• CAS NO: 299897-90-8
• Molecular Formula: C₁₁H₁₃N₃O₃
• Molecular Weight: 235.24
• Mol File: 299897-90-8.mol

Chemical Properties

• Melting Point: 246-248°C
• Appearance: /
• CAS DataBase Reference: 2-NITRO-5-(1-PYRROLIDINYL)BENZENECARBOXAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-NITRO-5-(1-PYRROLIDINYL)BENZENECARBOXAMIDE(299897-90-8)
• EPA Substance Registry System: 2-NITRO-5-(1-PYRROLIDINYL)BENZENECARBOXAMIDE(299897-90-8)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 299897-90-8(Hazardous Substances Data)

Upstream product

• 123-75-1 pyrrolidine 
• 40763-96-0 2-nitro-5-chlorobenzamide 
• 41994-44-9 5-chloro-2-nitrobenzoyl chloride 

Downstream Products

• 314768-96-2 2-amino-5-(pyrrolidin-1-yl)benzamide 

Relevant articles and documents

Synthesis and cytotoxicity of 6-pyrrolidinyl-2-(2-substituted phenyl)-4-quinazolinones

In our continuing search for potential anticancer candidates, 2-(3-methoxyphenyl)-6-pyrrolidinyl-4-quinazolinone (JJC-1) was selected as the lead compound. Starting 5-pyrrolidinyl-2-aminobenzamide was prepared using standard methodology from 5-chloro-2-ni

GLUCOSE UPTAKE INHIBITORS

this invention provides compounds that modulate glucose uptake activity and cellular transport/uptake of glucose, and particularly GLUTS3, but also including but not limited to GLUT1-14 (SLC2A1-SLC2A14). Compounds of the invention are useful for treating diseases, including cancer, autoimmune diseases and inflammation, infectious diseases, and metabolic diseases.

2-Aryl-4-Quinazolinones And Their Pharmaceutical Compositions

Provided is a compound of the formula I or a pharmaceutically acceptable salt, solvate or stereoisomer thereof: wherein Ar represents R5, R6, R7, R8, R1′, R2′, R3′, R4

Molecular modelling, synthesis, cytotoxicity and anti-tumour mechanisms of 2-aryl-6-substituted quinazolinones as dual-targeted anti-cancer agents

Background and Purpose Our previous study demonstrated that 6-(pyrrolidin-1-yl)-2-(3-methoxyphenyl)quinazolin-4-one (HMJ38) was a potent anti-tubulin agent. Here, HMJ38 was used as a lead compound to develop more potent anti-cancer agents and to examine t

6-alkylamino- and 2,3-dihydro-3′-methoxy-2-phenyl-4-quinazolinones and related compounds: Their synthesis, cytotoxicity, and inhibition of tubulin polymerization

As part of our continuing search for potential anticancer candidates among 2-phenyl-4-quinolones and 2-phenyl-4-quinazolinones, two series of 6,7,2′,3′,4′,5′-substituted 2-phenyl-4-quinazolinones and 6,2′,3′,4′,5′-substituted 2,3-dihydro-2-phenyl-4-quinazolinones were synthesized and evaluated for cytotoxicity and as inhibitors of tubulin polymerization. In general, a good correlation was found between the two activities. Five of the 6-substituted heterocyclic 2-phenyl-4-quinozolinones (37-51) showed significant cytotoxicity against a panel of human tumor cell lines with EC50 values in the low micromolar to nanomolar concentration ranges. Compound 38 was the most potent of these compounds, as well as the most potent inhibitor of tubulin polymerization in this series. The activity of 38 was in the same range as those of the antimitotic natural products, colchicine, podophyllotoxin, and combretastatin A-4. Substituted 2-phenyl-4-quinazolinones and 2,3-dihydro-2-phenyl-4-quinazolinones also displayed highly selective cytotoxicity against the ovarian cancer 1A9 and P-gp resistant KB-VIN cell lines.

The Synthesis of Substituted 2-Aryl-4(3H)-Quinazolinones using NaHSO3/DMA. Steric Effect upon the Cyclisation-dehydrogenation Step

A number of 2-aryl substituted 6-pyrrolidino-4(3H)-quinazolinones are reported. They were synthesized in four steps starting from commercially available 5-chloro-2-nitrobenzoic acid. The key cyclisation-dehydrogenation step between 2-amino-pyrrolidinobenz